SC 13G: EXACT SCIENCES CORP

AI Summary

SC 13G filing by EXACT SCIENCES CORP.

Risk Assessment

Risk Level: low

FAQ

Filing Documents

• exas-20241004xsc13g.htm (SC 13G) — 78KB
• exas-20241004xex991.htm (EX-99.1) — 12KB
• 0001124140-24-000075.txt ( ) — 92KB

(a). Name of Issuer

Item 1(a). Name of Issuer MDxHealth SA

(b). Address of Issuer's Principal Executive Offices

Item 1(b). Address of Issuer's Principal Executive Offices CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 70 21

(a). Name of Person(s) Filing

Item 2(a). Name of Person(s) Filing (a) Genomic Health, Inc. (b) Exact Sciences Corporation

(b). Address of Principal Business Office or, if none, Residence

Item 2(b). Address of Principal Business Office or, if none, Residence (a) The business address of Genomic Health, Inc. is 5505 Endeavor Lane, Madison, WI 53719. (b) The business address of Exact Sciences Corporation is 5505 Endeavor Lane, Madison, WI 53719.

(c). Citizenship

Item 2(c). Citizenship (a) Genomic Health, Inc. – Delaware (b) Exact Sciences Corporation – Delaware

(d). Title of Class of Securities

Item 2(d). Title of Class of Securities Ordinary shares, no par value

(e). CUSIP Number

Item 2(e). CUSIP Number B5950S113

Not applicable

Item 3. Not applicable.

Ownership

Item 4. Ownership (a) Amount beneficially owned As of the date hereof, Genomic Health, Inc. owns 2,441,171 Ordinary Shares and warrants to purchase an additional 1,000,000 Ordinary Shares of the Issuer. Genomic Health, Inc. is a wholly owned subsidiary of Exact Sciences Corporation. Exact Sciences Corporation, through the ownership described herein may be deemed to beneficially own the Ordinary Shares directly owned by Genomic Health, Inc. (b) Percent of class See responses to Item 11 on the attached cover pages. (c) Number of shares as to which the person has (i) Sole power to direct the vote See responses to Item 5 on the attached cover pages. (ii) Shared power to direct the vote See responses to Item 6 on the attached cover pages. (iii) Sole power to dispose or to direct the disposition of See responses to Item 7 on the attached cover pages. (iv) Shared power to dispose or to direct the disposition of See responses to Item 8 on the attached cover pages.

Ownership of Five Percent or Less of a Class

Item 5. Ownership of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof each Reporting Person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following .

Ownership of More than Five Percent on Behalf of Another Person

Item 6. Ownership of More than Five Percent on Behalf of Another Person Not applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person Not applicable.

Identification and Classification of Members of the Group

Item 8. Identification and Classification of Members of the Group Not applicable.

Notice of Dissolution of Group

Item 9. Notice of Dissolution of Group Not applicable.

Certification

Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a–11. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated October 4, 2024 GENOMIC HEALTH, INC. By Name James Herriott Title Secretary EXACT SCIENCES CORPORATION By Name James Herriott Title Senior Vice President, General Counsel and Secretary Exhibit Index Exhibit No. Description 99.1 Joint Filing Agreement, dated as of October 4, 2024, by and among the Reporting Persons

View Full Filing

View this SC 13G filing on SEC EDGAR